{"prompt": "['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'proactively follow-up all data received via the electronic Diary Card and contact the', 'subject whenever deemed necessary.', 'During the contact with the subject, the site will determine whether the subject might', 'actually be experiencing an AECOPD (e.g. notifications that can be explained solely by', 'increased physical activity will not be considered):', 'If the site concludes that the subject is not experiencing an AECOPD, this should be', 'documented/ reported in the eCRF. Please refer to study procedures manual (SPM)', 'for more details on how to perform this.', 'If the site concludes that the subject may be experiencing an AECOPD, an AECOPD', 'visit will be scheduled as soon as possible after the onset of AECOPD symptoms as', 'recorded in the electronic Diary Card or confirmed by the subject (maximum', '96 hours after onset of symptoms and, if applicable, preferably before starting', 'treatment with antibiotics). The AECOPD onset date will be captured in the eCRF', 'and additional information about severity will be also collected.', '- In case the AECOPD is confirmed but no AECOPD visit can take place, the', 'site should record the information in the medical records subject files, and in', 'the CRF in medical records section and obtain all relevant information', 'regarding the AECOPD(hospital record, medical record etc) and record this in', 'the eCRF.', 'During the AECOPD visit, the investigator will confirm the occurrence of the AECOPD', 'based on clinical and medical judgement and based on the Anthonisen criteria, and will', 'record its date of onset. The end date of the AECOPD and its severity will be determined/', 'confirmed by the investigator/delegate during (a) follow-up phone call(s), which will take', 'place at least every 2 weeks until the AECOPD has resolved.', 'If an AECOPD occurs at the time when one of the scheduled [stable] study visits is', 'planned, it should be handled and recorded as an AECOPD visit, with all relevant', 'AECOPD visit study procedures performed and, if possible, the stable study visit should', 'be re-scheduled to a later date, when the subject is stable again and within the time', 'window specified in the protocol. However, in exceptional cases, in consultation with', 'GSK Biologicals, the concluding visit (Visit : 3, Month 12) may be exceptionally', 'conducted outside of the allowed interval, if deemed necessary by the investigator. The', 'reason for this should be documented in the eCRF.', 'The investigator/site must engage their best efforts to reach the patients, however, if the', 'site does not succeed in contacting the patient, the reason should be recorded and an', 'explanation given about what occurred. For example, the subject could be hospitalized', 'or could visit a different physician (and in that case medical record should be', 'obtained), or the subject is on holidays or not able to go the site.', '19-OCT-2018', '87', '75661ebdab2e949f7a1f1bc2071b9dec72aceccf']['CONFIDENTIAL', '201112 (EPI-NTHI-001 BOD APA)', 'Protocol Amendment 3 Final', 'Section 3.1.1.1 Date of onset and end date of AECOPD', 'The date of onset is the first day (of at least 2 consecutive days) of worsening symptoms', 'of COPD, as determined by the Investigator according to the Anthonisen criteria.', 'The end date should be based on when the investigator determines that the AECOPD', 'symptoms have resolved. In determining this end date, consideration should be given to', 'symptoms recorded in the electronic Diary Card and subject assessment during the', 'phone calls.', 'Section 4.1 Number of subjects/centres', 'The target is to enrol approximately 200 eligible moderate to very severe COPD patients.', 'All subjects should be recruited within the period of 1 year.', 'Section 4.2 Inclusion criteria for enrolment', 'Confirmed diagnosis of moderate to very severe COPD based on post-bronchodilator', 'spirometry (i.e. forced expiratory volume in 1 second [FEV1 over forced vital', 'capacity [FVC] ratio [FEV1/FVC] <0.7 AND and FEV1 < 80% predicted [GOLD', 'grades 2, 3 and 4].', 'Stable COPD patient* with documented history* (e.g. medical record verification)', 'of at least 1 moderate or severe AECOPD within the 12 months before study entry.', '* Patient for whom the last episode of AECOPD is resolved for at least 30 days at', 'the time of study entry. **Note: A documented history of a COPD exacerbation', '(e.g., medical record verification) is a medical record of worsening COPD', 'symptoms that required systemic/oral corticosteroids and/or antibiotics (for a', 'moderate exacerbation) or hospitalization (for a severe exacerbation). Prior use of', 'antibiotics alone does not qualify as an exacerbation history unless the use was', 'associated with treatment of worsening symptoms of COPD, such as increased', 'dyspnea, sputum volume, or sputum purulence (color). Subject verbal reports are', 'not acceptable.', 'Current or former tobacco smoker (cigarette) with a smoking history of > 10 pack-', 'years OR a subject exposed to biomass smoke for 20 years. [Guoping Hu 2010]', 'Section 4.3 Exclusion criteria for enrolment', 'Undergone or planning lung surgery within 12 months from study entry-Undergone', 'or has had lung surgery 12 months before, or plans to have lung surgery 12', 'months after, study entry.', 'Administration of antibiotics within 1 month of study entry OR continuous', 'administration of antibiotics (defined as more than 1 month-30 days in total) within', 'the three months 90 days before study entry.', 'Systemic administration of corticosteroids (PO/IV/IM) for more than 14', 'consecutive days within 90 days prior to informed consent.', '19-OCT-2018', '88', '5661ebdab2e949f7a1f1bc2071b9dec72aceccf']\n\n###\n\n", "completion": "END"}